RegulatoryOfficial
EMA recommends Gazyvaro for adults with active systemic lupus erythematosus, SÚKL reports
🇨🇿 SÚKL · Mon 16 Nov 2026
The EU regulator has backed extending obinutuzumab to moderate-to-severe active SLE as add-on therapy, according to the Czech authority SÚKL; a Commission decision is still to come.
The Czech State Institute for Drug Control (SÚKL) reported on 16 November 2026 that the European Medicines Agency (EMA) has recommended extending the EU use of Gazyvaro (obinutuzumab) to a new indication: systemic lupus erythematosus (SLE).
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Article written by VigiEye from the official source (SÚKL). AI-assisted; check the source before acting.
More Regulatory
All →
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
🇺🇸 Unicycive Therapeutics, Inc. (UNCY) · Mon 16 Nov 2026
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
Noema Pharma AG · Mon 16 Nov 2026
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026
Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
🇺🇸 Invivyd, Inc. (IVVD) · Mon 16 Nov 2026